<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04080232</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2017/05</org_study_id>
    <nct_id>NCT04080232</nct_id>
  </id_info>
  <brief_title>Study of Pulmonary MRI for the Diagnosis of Bronchiolitis Obliterans Syndrome After Allogeneic Stem Cell Transplantation</brief_title>
  <acronym>IRM-A</acronym>
  <official_title>Study of Pulmonary MRI for the Diagnosis of Bronchiolitis Obliterans Syndrome After Allogeneic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SFGM-TC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bronchiolitis Obliterans Syndrome (BOS) is a major complication of Hematopoietic Stem cell&#xD;
      Transplantation (HSCT) occurring in the context of chronic GVHD and associated with a poor&#xD;
      prognosis. The diagnosis of BOS is based on functional (Pulmonary Functional Tests) and&#xD;
      morphological criteria (chest CT-scan). Early diagnosis of BOS represents an unmet need and&#xD;
      would facilitate early therapeutic interventions. Lung MRI has been recently developed with&#xD;
      new sequences facilitating morphological and functional lung analysis in various inflammatory&#xD;
      contexts. The goal of this study is to compare the morphological performances of chest&#xD;
      CT-scan and MRI&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing allogeneic stem cell transplantation may develop non-infectious&#xD;
      respiratory complication related to chronic graft versus host disease and called&#xD;
      bronchiolitis obliterans syndrome (BOS). The occurrence of BOS is associated with a decreased&#xD;
      survival reaching 13% at 5 years (Dudek et al, BBMT 2003). Thus, screening and diagnosis of&#xD;
      BOS appear as a priority of post-transplant patients monitoring, in order to begin early&#xD;
      therapy if needed. To this end, patients undergo systematic and regular screening using&#xD;
      pulmonary function tests (PFTs). In case of abnormal PFTs, tests are completed the screening&#xD;
      of respiratory infections and chest computed tomographic scan (CT-scan) is performed. A&#xD;
      report from the National Institute of Health described the following criteria required for&#xD;
      the diagnosis of BOS : FEV1/vital capacity &lt; 0.7, FEV1 &lt; 75% or a decline &gt;/= 10% from&#xD;
      baseline, residual volume &gt; 120%, absence of documented infection, and the presence of&#xD;
      CT-scan signs suggestive of BOS : air trapping by expiratory CT or small airway thickening or&#xD;
      bronchiectasis.&#xD;
&#xD;
      BOS severity depends on the development of fibrotic and fixed damages, poorly responding to&#xD;
      therapies. New tools are needed in order to favor early BOS diagnosis.&#xD;
&#xD;
      A recent study from our center showed that repeated CT-scans in stem cell transplant patients&#xD;
      is associated with increased risk of neoplasia. In addition, recent studies from our center&#xD;
      evaluated the use of pulmonary MRI providing good performance without X-ray exposure (Dournes&#xD;
      G et al, Radiology 2015 et Dournes G et al, Eur Radiol 2015).&#xD;
&#xD;
      More recently, Renne et al (Radiology 2015) studied the performance of pulmonary MRI coupled&#xD;
      with oxygen transfer analysis for the diagnosis of chronic lung allograft dysfunction. This&#xD;
      study showed altered imaging parameters in patients developing BOS, including patients with&#xD;
      early BOS stage (0p stage).&#xD;
&#xD;
      As pathogenic mechanisms seem to be shared between post-stem cell transplant and post-lung&#xD;
      transplant BOS, we hypothesize that pulmonary MRI with oxygen transfer analysis and ultra&#xD;
      short echo time may represent a non-invasive, non-irradiating and sensitive research tool for&#xD;
      the detection and quantification of pulmonary lesions in patients screened for post-stem cell&#xD;
      transplant BOS.&#xD;
&#xD;
      Thus, 20 patients who underwent allogeneic stem cell transplantation and show abnormal&#xD;
      respiratory function over a 2 year period study are expected. They will be included according&#xD;
      to the following criteria : age &gt; 18 yo, &gt; 3 months post-transplant, absence of documented&#xD;
      pulmonary infection, or with a minimum of 6 weeks after a documented pulmonary infection, and&#xD;
      the following BOS criteria : abnormal PFTs (FEV1/VC &lt; 0.7, FEV1 &lt; 0.75, residual volume &lt;&#xD;
      120% of expected value) and/or chest CT-scan showing air trapping or small airway thickening.&#xD;
      Similarly to lung transplant criteria, stage 0p BOS defined according to FEF25-75 values&#xD;
      (Estenne et al, JHLT 2002), for which pulmonary MRI with oxygen transfer may guide to early&#xD;
      BOS diagnosis, will be added.&#xD;
&#xD;
      Patients who give their consent will perform a pulmonary MRI, in the absence of&#xD;
      contraindication, using different sequences to evaluate morphologic and functional&#xD;
      performances of pulmonary MRI. We will compare CT-scan and MRI performances using blinded&#xD;
      analysis from two radiologists.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2020</start_date>
  <completion_date type="Anticipated">September 24, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 24, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>lung MRI concordance as compared to chest CT-scan</measure>
    <time_frame>Baseline</time_frame>
    <description>lung MRI concordance as compared to chest CT-scan for the description of morphological abnormalities necessary for the diagnosis of BOS after HSCT. It will be evaluated using lung MRI performed after inclusion (Baseline) using a standardized procedure. The agreement between MRI and chest CT-scan for the presence or absence of the following features, will be measured at the segmental level: airway thickening, bronchiectasis, air trapping.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bhalla Score precision in morphological MRI</measure>
    <time_frame>Baseline</time_frame>
    <description>Measure of Bhalla Score precision in morphological MRI for the diagnosis of post-transplant BOS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bhalla Score in CT scan</measure>
    <time_frame>Baseline</time_frame>
    <description>Bhalla Score in CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxygen transfer capacity</measure>
    <time_frame>Baseline</time_frame>
    <description>Measure of oxygen transfer capacity (percentage of intra-pulmonary signal variation before and after inhalation of oxygen);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Force Expiratory Volume</measure>
    <time_frame>Baseline</time_frame>
    <description>Force Expiratory Volume (FEV, l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1/VC</measure>
    <time_frame>Baseline</time_frame>
    <description>FEV1/VC (Tiffeneau),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual volume</measure>
    <time_frame>Baseline</time_frame>
    <description>Residual volume (l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total lung capacity</measure>
    <time_frame>Baseline</time_frame>
    <description>Total lung capacity (l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BOS stages</measure>
    <time_frame>Baseline</time_frame>
    <description>BOS stages (0 : FEV1 &gt; 90%, and FEF25-75 &gt; 75% from baseline; 0p : 10-19% decrease in FEV1, and/or by a &gt;/= 25% decrease in FEF 25-75 from baseline; 1: FEV1 60-79% ; 2: FEV1 40-59% ; 3: FEV1&lt;/= 39)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intra-observer repeatability of the Bhalla score in CT scan</measure>
    <time_frame>Baseline</time_frame>
    <description>Intraclass coefficient and Bland-Altman's test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intra-observer repeatability of the Bhalla score in MRI</measure>
    <time_frame>Baseline</time_frame>
    <description>Intraclass coefficient and Bland-Altman's test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intra-observer repeatability of the measure of oxygen transfer capacity</measure>
    <time_frame>Baseline</time_frame>
    <description>Intraclass coefficient and Bland-Altman's test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inter-observer reproducibility of the Bhalla score in CT scan</measure>
    <time_frame>Baseline</time_frame>
    <description>Intraclass coefficient and Bland-Altman's test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inter-observer reproducibility of the Bhalla score in MRI</measure>
    <time_frame>Baseline</time_frame>
    <description>Intraclass coefficient and Bland-Altman's test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inter-observer reproducibility of the measure of oxygen transfer capacity</measure>
    <time_frame>Baseline</time_frame>
    <description>Intraclass coefficient and Bland-Altman's test</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Bronchiolitis Obliterans</condition>
  <arm_group>
    <arm_group_label>Lung MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lung MRI concordance as compared to chest CT-scan for the description of morphological abnormalities necessary for the diagnosis of BOS after HSCT. It will be evaluated using lung MRI performed after inclusion (D0) using a standardized procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>lung MRI</intervention_name>
    <description>lung MRI (1.5T Siemens Aera) using the following sequences: 3D Fast gradient-echo pulse sequences with ultra-short echo time (UTE), acquisitions at end-inspiration breath hold, end-expiration breath hold, and free-breathing using an echonavigator positioned on the diaphragm, acquisitions using routine pulse sequences (SSFP, T2FSE) and the administration of oxygen during the MRI: O2 will be administered at 15L/min during 6 minutes.</description>
    <arm_group_label>Lung MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient ≥ 18 yo ;&#xD;
&#xD;
          -  Patient who underwent an allogeneic stem cell transplantation (SCT)&#xD;
&#xD;
          -  &gt; 3 months post-SCT&#xD;
&#xD;
          -  With evidence of&#xD;
&#xD;
               -  respiratory symptoms, and/or&#xD;
&#xD;
               -  Pathological PFTs defined by : obstructive syndrome (FEV1 :vital capacity/CVF &lt;&#xD;
                  0.7), FEV1 &lt; 0.75 of pre-SCT values, residual volume &gt; 120%, and/or ;&#xD;
&#xD;
               -  Altered PFTs consistent with 0p stage described in lung transplantation BOS: FEV1&#xD;
                  decline ≥ 10 % and/or FEF25-75 decline ≥ 25% compared to pre-SCT PFTs, and/or ;&#xD;
&#xD;
               -  Abnormal chest CT-scan with findings consistent with BOS: evidence of air&#xD;
                  trapping on expiratory CT-scan, bronchiectasis, and/or airway thickening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication for MRI ;&#xD;
&#xD;
          -  Contraindication of oxygen administration ;&#xD;
&#xD;
          -  Decompensation of altered respiratory function ;&#xD;
&#xD;
          -  Acute respiratory infection (bacterial, fungal or viral) documented in the last 6&#xD;
             weeks ;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Edouard Forcade, MD</last_name>
    <phone>335 57 65 65 11</phone>
    <email>edouard.forcade@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elodie Blanchard, MD</last_name>
    <email>elodie.blanchard@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edouard Forcade, MD</last_name>
      <email>edouard.forcade@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 4, 2019</study_first_submitted>
  <study_first_submitted_qc>September 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung MRI performance</keyword>
  <keyword>UTE</keyword>
  <keyword>quantification</keyword>
  <keyword>oxygen transfer</keyword>
  <keyword>Bronchiolitis Obliterans syndrome</keyword>
  <keyword>allogeneic stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Bronchiolitis Obliterans</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

